Biochemical and immunohistochemical analysis of glycosaminoglycans in inflamed and non-inflamed intestinal mucosa of patients with Crohn's disease

International Journal of Colorectal Disease

Volumn 20, Issue 4, 2005, Pages 295-304

  Belmiro, Celso L R ^a   Souza, Heitor S P ^a   Elia, Celeste C S ^a   Castelo Branco, Morgana T L ^a   Silva, Flavia R ^a   Machado, Rosane L ^a   Pavão, Mauro S G ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Extracellular matrix; Glycosaminoglycans; Inflammatory bowel disease; Intestinal mucosa

Indexed keywords

AZATHIOPRINE; CHONDROITIN SULFATE; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HYDROCORTISONE; INTERCELLULAR ADHESION MOLECULE 1; METRONIDAZOLE; PREDNISONE; URONIC ACID;

ADULT; AGAR GEL ELECTROPHORESIS; ANALYSIS OF VARIANCE; ARTICLE; BASEMENT MEMBRANE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; COLON ADENOCARCINOMA; CONFOCAL MICROSCOPY; CROHN DISEASE; DISEASE COURSE; DRY WEIGHT; EXTRACELLULAR MATRIX; FEMALE; GLYCOSAMINOGLYCAN METABOLISM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; INTESTINE RESECTION; ION EXCHANGE CHROMATOGRAPHY; LAMINA PROPRIA; MALE; PRIORITY JOURNAL; REDUCTION;

ADULT; CROHN DISEASE; DISEASE PROGRESSION; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINAL MUCOSA; MALE; MIDDLE AGED;

EID: 21344438652     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-004-0677-2     Document Type: Article

References (33)

1. Pender SLF, Breese EJ, Günther U et al (1998) Suppression of T cell-mediated injury in human gut by interleukin 10: Role of matrix metalloproteinases. Gastroenterology 115:573-583
2. Pender SLF, Tickle SP, Docherty AJP, Howie D, Wathen NC, MacDonald TT (1997) A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 158:1582-1590
3. Schuppan D, Riecken EO (1990) Molecules of the extracellular matrix: potential role of collagens and glycoproteins in intestinal adaptation. Digestion 46:2-11
4. Malik AB, Lynen JL, Cooper JA (1989) Endothelial barrier function. J Invest Dermatol 93:62S-67S 10.1111/1523-1747.ep12581072
5. Powers MR, Blumenstock FA, Cooper JA, Malik AB (1989) Role of albumin arginyl sites in albumin-induced reduction of endothelial hydraulic conductivity. J Cell Physiol 141:558-564
6. Rosenzweig LJ, Kanwar YS (1982) Removal of sulfated (heparan sulfate) or non-sulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of glomerular basement membrane to 125 I-bovine serum albumin. Lab Invest 47:177-184
7. Sunergren KP, Fairman RP, deBlois GG, Glauser FL (1987) Effects of protamine, heparanase and hyaluronidase on endothelial permeability and surface charge. J Appl Physiol 63:1987-1992
8. Comper WD, Zamparo O (1990) Hydrodynamic properties of connective tissue polysaccharides. Biochem J 269:561-564
9. Comper WD, Laurent TC (1978) Physiological function of connective tissue polysaccharides. Physiol Rev 58:255-315 1:CAS:528:DyaE1cXntFyrsA%3D%3D
10. Kjellé L, Lindahl U (1991) Proteoglycans: Structures and interactions. Annu Rev Biochem 60:443-475 1:CAS:528:DyaK3MXlsFeitLg%3D
11. Lindahl U, Höö M (1978) Glycosaminoglycans and their binding to biological macromolecules. Annu Rev Biochem 47:385-417 10.1146/ annurev.bi.47.070178.002125
12. Ahrenstedt O, Knutson L, Hallgren R, Gerdin B (1992) Increased luminal release of hyaluronan in uninvolved jejunum in active Crohn's disease but not in inactive disease or in relatives. Digestion 52:6-12
13. Filipe MI, Dawson I (1970) The diagnostic value of mucosubstances in rectal biopsies from patients with ulcerative colitis and Crohn's disease. Gut 11:229-234
14. Murch SH, MacDonald TT, Walker-Smith JA, Levin M, Lionetti P, Klein NJ (1993) Disruption of sulfated glycosaminoglycan in intestinal inflammation. Lancet 341:711-714 10.1016/0140-6736(93)90485-Y
15. Sheehan DG, Jervis HR (1976) Comparative histochemistry of gastrointestinal mucosubstances. Am J Anat 146:103-132
16. Cardoso LEM, Mourão PAS (1994) Arterial connective tissue alteractions in thalassemia major: A biochemical study of a case with severe iron overload. Braz J Med Biol Res 27:509-514
17. Harvey RF, Bradshaw MJ (1980) Measuring Crohn's disease activity. Lancet 1:1134-1135 10.1016/S0140-6736(80)91577-9
18. Seldenrijk CA, Morson BC, Meuwissen SG, Schipper NW, Lindeman J, Meijer CJ (1991) Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: Diagnostic implications. Gut 2:1514-1520 1:STN:280:By2C38fnslM%3D
19. Bitter T, Muir HM (1962) A modified uronic acid carbazole reaction. Anal Biochem 4:330-334 1:CAS:528:DyaF3sXnsVyrtw%3D%3D
20. Dietrich CP, Dietrich SMC (1976) Electrophoretic behaviour of acidic mucopolysaccharides in diamine buffers. Anal Biochem 70:645-647 10.1016/ 0003-2697(76)90496-6
21. Pavão MSG, Aiello KRM, Werneck CC et al. (1998) Highly sulfated dermatan sulfates from ascidians. Structure versus anticoagulant activity of these glycosaminoglycans. J Biol Chem 273:27848-27857 10.1074/jbc.273.43.27848
22. Shievely JE, Conrad HE (1976) Formation of anhydrosugars in the chemical depolymerization of heparin. Biochemistry 15:3932-3942
23. Pender SL, Lionetti P, Murch SH, Wathan N, MacDonald TT (1996) Proteolytic degradation of intestinal mucosal extracellular matrix after lamina propria T cell activation. Gut 39:284-290
24. Tsara ME, Papageorgacopoulou N, Karavias DD, Theocharis DA (1995) Distribution and changes of glycosaminoglycans in neoplasias of rectum. Anticancer Res 15:2107-2112
25. Alini M, Losa GW (1991) Partial characterization of proteoglycans isolated from neoplastic and nonneoplastic human breast tissues. Cancer Res 51:1443-1447
26. Iozzo RV, Wight TN (1982) Isolation and characterization of proteoglycans synthesized by human colon and colon carcinoma. J Biol Chem 257:11135-11144
27. Kovalszky I, Pogang G, Molnar G et al. (1990) Altered glycosaminoglycan composition in reactive neoplastic human liver. Biochem Biophys Res Commun 167:883-890 10.1016/0006-291X(90)90606-N
28. Rapraeger AC, Krufka A, Olwin BB (1991) Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252:1705-1708
29. Szabo S, Kusstatscher S, Sakoulas G, Sandor Z, Vincze A, Jadus M (1995) Growth factors: New 'endogenous drugs' for ulcer healing. Scand J Gastroenterol 210:15-18
30. Klagsbrun M, Baird A (1991) A dual receptor system is required for basic fibroblast growth factor activity. Cell 67:229-231 10.1016/ 0092-8674(91)90173-V
31. Day R, Forbes A (1999) Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Lancet 354:62-65 10.1016/ S0140-6736(98)09267-8
32. Penc SF, Pomahac B, Winkler T et al. (1998) Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function. J Biol Chem 273:28116-28121 10.1074/jbc.273.43.28116
33. Penc SF, Pomahac B, Eriksson E, Detmar M, Gallo RL (1999) Dermatan sulfate activates nuclear factor-kappa b and induces endothelial and circulating intercellular adhesion molecule-1. J Clin Invest 103:1329-1335